BioAtla’s $65 Million Underwritten Offering of Common Stock

Martina Bellini North America Legal Chronicle
Tagged:

Orrick advised BioAtla on the deal.Clinical-stage biotechnology company BioAtla, Inc. (Nasdaq: BCAB) announced the sale of 9,745,128 shares of its common stock at a price of $6.67…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:
Martina Bellini

Author: Martina Bellini

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here